Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18552504 | ANTI-TAU ANTIBODIES AND USES THEREOF | Final Rejection | Janssen Biotech, Inc. |
| 18318912 | ALDH1 ANTIGEN-PULSED DENDRITIC CELLS | Final Rejection | The Regents of the University of Michigan |
| 18208178 | IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS AND METHODS FOR DIAGNOSING AND TREATING CANCER | Non-Final OA | Agilent Technologies, Inc. |
| 18043497 | COMPOSITIONS AND METHODS FOR TARGETING PLASMODIUM MALE GAMETE PROTEIN TO BLOCK MALARIA PARASITE TRANSMISSION | Non-Final OA | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE |
| 18025883 | A Scoring Method for an Anti-B7H4 Antibody-Drug Conjugate Therapy | Final Rejection | Medimmune Limited |
| 18267835 | POLYPEPTIDE | Non-Final OA | UCL Business Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy